FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer

Corcept Therapeutics (CORT) announced the FDA has accepted its New Drug Application (NDA) for relacorilant for platinum-resistant ovarian cancer, with a decision anticipated by July 11, 2026. This NDA is supported by positive Phase III ROSELLA and Phase II study data, which indicated improved progression-free survival and a potential new standard of care. This development follows CORT's December 2024 NDA submission for relacorilant in Cushing's syndrome, with a PDUFA date of December 30, 2025. The potential approval of relacorilant in multiple indications is critical for Corcept, aiming to diversify revenue streams beyond its sole marketed drug, Korlym, and capitalize on its strong year-to-date share performance of 42.1%.

Analysis

Corcept Therapeutics has achieved a significant regulatory milestone with the FDA's acceptance of its New Drug Application (NDA) for relacorilant in platinum-resistant ovarian cancer. This action sets a PDUFA target date of July 11, 2026, providing a long-term catalyst for the company. The submission is underpinned by positive data from the pivotal phase III ROSELLA study, which met its primary endpoint of improved progression-free survival, suggesting a potential to establish a new standard of care. This development adds to a nearer-term catalyst, as an NDA for relacorilant in Cushing's syndrome is also under review with a PDUFA date of December 30, 2025. These potential approvals are critical for Corcept's strategy to diversify its revenue, which is currently dependent on its sole marketed drug, Korlym. Korlym's sales grew a robust 13.2% year-over-year to $351.6 million in the first half of 2025, but the pipeline's success is key to de-risking the business model. The company's stock performance, with a 42.1% year-to-date rally outperforming the industry's 12.9% rise, reflects strong investor optimism regarding these pipeline assets, despite the article noting a conflicting Zacks Rank #4 (Sell) designation.

Key Decisions for Investors

• Investors should closely monitor the two distinct PDUFA dates for relacorilant, as the December 30, 2025 decision for Cushing's syndrome represents the most immediate value inflection point, followed by the ovarian cancer decision in July 2026.
• Given the stock's significant 42.1% year-to-date rally, it is crucial to assess whether the potential of the dual relacorilant approvals is already priced in, while also tracking the sales performance of the existing drug, Korlym, which remains the sole revenue source.
• The conflicting signal of a positive FDA milestone against a cited Zacks Rank of #4 (Sell) warrants further due diligence into potential underlying concerns such as valuation, market competition for Cushing's syndrome, or other risk factors not detailed in the article.